2025 annual results: Equasens reports a solid performance across all financial indicators

Core Insights - Equasens reported solid financial performance for FY 2025, with revenue reaching €236.5 million, reflecting a 9.1% increase compared to FY 2024 [4][7] - The company continues to focus on technological innovation and strategic acquisitions, including the recent acquisition of Erevo, which enhances its digital training offerings [5][34] Financial Performance - Revenue for FY 2025 was €236.5 million, up from €216.8 million in FY 2024, marking a 9.1% increase [4][7] - Recurring EBITDA increased to €66.7 million, also a 9.1% rise, indicating effective cost control [4][7] - Current operating income rose to €48.2 million, a 6.8% increase, influenced by investments in new healthcare data infrastructure [4][7] - Net profit increased by 8.8% to €41.1 million, supporting a proposed dividend of €1.40 per share [7][31] Division Highlights - PHARMAGEST Division: Revenue grew to €172.2 million (+5.3%), with current operating income at €32.0 million (+4.2%) [10][14] - AXIGATE LINK Division: Revenue increased to €37.6 million (+17.0%), with a current operating income of €11.0 million (+8.0%) [10][21] - E-CONNECT Division: Revenue surged to €14.7 million (+31.4%), although current operating income saw a modest increase of 2.2% [10][22] - MEDICAL SOLUTIONS Division: Revenue reached €10.0 million (+26.1%), with current operating income improving significantly [10][23] - FINTECH Division: Revenue stabilized at €2.0 million, with a current operating income showing a notable improvement [10][33] Cash Flow and Financial Position - Cash flow after interest and tax increased to €56.7 million, up from €47.7 million in FY 2024 [26][27] - Gross cash balance at year-end was €136.8 million, with net cash amounting to €83.6 million, an increase of €4.1 million [29][27] Strategic Initiatives - The acquisition of Erevo is expected to strengthen Equasens' position in the healthcare education market and create synergies with existing training offerings [34] - The company is focusing on integrating AI capabilities into its software solutions to enhance decision support and operational efficiency [39][40] Governance Changes - Thierry Chapusot, Chairman of the Board, will not seek renewal of his appointment, marking a significant governance change [35][36] - François-Pierre Marquier has been appointed Deputy CEO, effective April 1, 2026 [36][37] Future Outlook - Equasens aims to strengthen its leadership in the digital health solutions market, with a continued focus on technological innovation and AI integration [38][39]